REPLY
28.4.2022 14:02:13 CEST | Business Wire | Press release
Today Reply inaugurates Area42 , the new applied research centre focused on developing the most innovative technologies. The Area42 “corner Labs” are driven by cutting-edge work in the areas of Autonomous Warehouse, Last Mile Delivery, Robotics, Connected Products, Blockchain and the Metaverse . Reply’s experts are working on these technologies on a daily basis, transforming ideas into innovative prototypes, exploiting their full potential and applying them to real use industrial cases.
The Area42 Laboratories are the distinctive component of Reply’s new Turin headquarters, which covers an area of over 20,000 square metres. Each workspace has been completely renovated and optimised in line with the Group’s new working models, which focus on a more open and collaborative approach. Reply will host its customers in the new spaces, collaborating with them to experiment, incubate new concepts, and test the latest technologies in a way that enables digital products and services to be adapted to their specific innovation context.
The 6 Area42 Laboratories focus on the key themes representing the most advanced frontiers of innovation for the industrial world:
- Autonomous Warehouse, the Area42 laboratory where solutions are studied and developed for the autonomous management of warehouse activities, thanks to the use of autonomous drones and vehicles capable of interfacing with innovative warehouse management platforms such as LEA Reply;
- Last mile delivery , the Area42 laboratory focused on the mobility of self-driving vehicles and robots within pre-defined spaces (e.g., campuses, hospitals, factories, etc.) that are capable of interacting with the surrounding environment;
- Robotics , the Area42 laboratory that combines Artificial Intelligence technologies with robotics to study the agility of autonomous robots and use scenarios focused on the interaction between the latter and large environments requiring repetitive maintenance and control activities;
- Connected Products, the Area42 space focused on the design and development of connected products and services, from the prototyping of devices to the creation of front-end applications, also thanks to the support of IoT accelerators;
- Blockchain , in the context of an ever-greater evolution of the concepts of smart cities and shared mobility, this Area42 laboratory experiments with the application of blockchain technologies for enabling real scenarios based on the Digital Identity of Vehicles;
- Metaverse, the Area42 laboratory focused on the application and integration of Mixed Reality solutions to create immersive applications in virtual environments, where users can enter and move around and where virtual and physical objects co-exist.
“The Area42 laboratories represent a unicum in the modern technological panorama,” affirmed Filippo Rizzante, Reply CTO. “Here, we give life to new and innovative concepts and apply the latest technologies to provide solutions capable of creating value for business and for society as a whole. We experiment with and implement innovative ideas that have a strategic impact and generate a competitive advantage for our customers. Currently, our focus is on six highly topical issues, but technological evolution will always continue to drive us further, in line with what has always been our approach at Reply: to prepare for and make the future a tangible reality”.
Area42 joins Reply’s existing laboratories in Europe: the Test Automation Centre , focused on the automated monitoring and testing of the quality of business-critical products and services; the IoT Validation Lab , where interconnected solutions are validated and also integrated with Reply’s new Turin headquarters, creating the most advanced hub of laboratories for the industry sector; Area 360, the centre for augmented and virtual reality based in Milan which was created to support businesses; the Immersive Experience Lab in Munich, which experiments with next-generation immersive experiences; the Cyber Security Lab , in Cologne, focused on the study and testing of cyber threats; and finally, Reply’s new labs opening soon in London which will be dedicated to robotics, edge computing and sensory technologies.
“The creation of Area42 is part of a broader project of excellence in terms of property redevelopment that we have initiated here in Turin”, continues Tatiana Rizzante. “While carefully respecting the constraints imposed by the Superintendency of Architectural Heritage in relation to what is certainly considered a symbol of modern architecture, we wanted to create harmonious and stimulating spaces to work, exchange ideas and carry out research. The interconnection of spaces created to accommodate different functions – from individual to team work, from the sharing of projects to leisure time, from lounges to the most advanced laboratories – creates a fluid and open space. Our team of experts, but also our customers and partners, can thus take advantage of a truly immersive experience and experiment with technological innovation”.
The Lingotto building that hosts Area42, located in Via Nizza no. 250 in Turin and recently acquired by the Group, has been the subject of a major renovation project which, together with works currently under way at the former Caserma de Sonnaz, make it possible to revive and reinterpret – with a contemporary touch – two iconic buildings for the city of Turin.
The projects are driven by the concepts of innovation, collaboration and well-being, placing the focus on the two main protagonists: people and research.
The completely renovated Lingotto building offers open spaces and new paths, created to facilitate business relationships and enlivened by the most current languages and codes. Reply’s people find themselves immersed in a large, multi-functional space with areas off limits to mobile phones and meetings to facilitate concentration. Common areas are dedicated not only to brainstorming, but also to sports, catering and leisure, for a more effective sharing of ideas and socialisation in the workplace: an active and ever-evolving ecosystem.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005169/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
